- Methodology article
- Open Access
Simultaneous silencing of multiple RB and p53 pathway members induces cell cycle reentry in intact human pancreatic islets
© Tamaki et al.; licensee BioMed Central Ltd. 2014
- Received: 2 April 2014
- Accepted: 19 September 2014
- Published: 11 October 2014
Human pancreatic islet structure poses challenges to investigations that require specific modulation of gene expression. Yet dissociation of islets into individual cells destroys cellular interactions important to islet physiology. Approaches that improve transient targeting of gene expression in intact human islets are needed in order to effectively perturb intracellular pathways to achieve biological effects in the most relevant tissue contexts.
Electroporation of intact human cadaveric islets resulted in robust and specific suppression of gene expression. Two genes were simultaneously suppressed by 80% from baseline levels. When multiple (up to 5) genes were simultaneously targeted, effective suppression of 3 of 5 genes occurred. Enzymatic pretreatment of islets was not required. Simultaneous targeting of RB and p53 pathway members resulted in cell cycle reentry as measured by EDU incorporation in 10% of islet nuclei.
At least three genes can be effectively suppressed simultaneously in cultured intact human pancreatic islets without disruption of islet architecture or overt alterations in function. This enabled the effective modulation of two central growth control pathways resulting in the phenotypic outcome of cell cycle reentry in postmitotic islet cells. Transient exposure to multiple siRNAs is an effective approach to modify islets for study with the potential to aid clinical applications.
- Intact human islets
- Cell cycle reentry
We report the simultaneous suppression of multiple genes in intact adult human pancreatic islets. The study of human islets is hindered by obstacles including difficulty of maintaining islet cells in vitro but within their native complex tissue environment, the intact islet, and difficulty modulating gene expression in a majority of islet cells without significantly damaging islet viability, function and architecture. The complexity of islet biology results in part from the physical interactions and communication between the various islet cell types [1–4]. This intercellular network is disrupted when islets are dissociated and cultured, which is a commonly used approach to study islet cells that facilitates transfection or infection with virus (reviewed in ). By contrast, modification of islet cell gene expression in the context of intact intercellular relationships should increase the relevance of the information obtained. Thus, the establishment of techniques that expand our ability to study intact islets is merited.
Translational efforts towards clinical applications using intact islets could also benefit from the advances described here. As transplantation of intact islets advances in clinical trials, clinical applications requiring direct modification of gene expression to improve islet survival and engraftment would likely rely on transient modifications that do not result in permanent integration of genetic constructs. In the case of islet transplantation the period of ex vivo culture prior to transplantation affords an opportunity for transient delivery of siRNA to modulate gene expression in efforts to improve transplantation protocols [6, 7]. Moreover, the importance of developing protocols that facilitate mechanistic studies using human islets is underscored by the observations that insights gained from studies of rodent islets often do not translate directly when applied to human tissue [8, 9].
Islet study also has inherent technical challenges shared by other cell types. Although it has been demonstrated that single molecules can significantly influence human beta cell mitogenic responses , the ability to commandeer positive and negative proliferation pathways requires modulation of multiple genes at a time. This is in part due to inherent genetic redundancy that often makes single gene modulation insufficient, and also to the need to evaluate upstream and downstream events relating to an initial perturbation. For example, the retinoblastoma (RB) pathway contains three partially redundant pocket proteins, pRB, p107 and p130 in addition to multiple upstream and downstream modulators and effectors . A generally assumed limitation of RNA interference experiments has been the number of targeted genes that can be directly suppressed at one time. In islets, to date single genes have been efficiently suppressed by electroporation . However, whether it is possible in intact islets to efficiently silence multiple genes simultaneously, which may be obligatory to promote robust biological endpoints remains unknown. A number of potentially complicating factors include delivery of adequate amounts of siRNA molecules into individual cells, saturation of the RISC complex, and toxicity to individual cells throughout the islet.
Here we use electroporation to suppress gene expression using siRNA in intact human islets. We show that suppression of multiple transcripts can occur simultaneously using an approach that preserves morphology, viability and glucose responsiveness. Suppression of genes within the RB and p53 pathways illustrates the capacity to use siRNA to dissect functional interactions among multiple pathway members. These findings should prove useful, as they demonstrate a potent and safe approach to transiently modulate gene expression within the native islet environment.
We sought to determine an optimal method for modulation of gene expression in intact adult human islets that would be transient and would be minimally disruptive in terms of islet architecture, function and viability. In order to be a sufficiently potent approach to achieve biological endpoints, another goal was to successfully modulate more than a single gene at a time. Prior studies by others have shown that adenoviral infection can target the surface cells of the islet, but not the core [13–17], and it has recently been shown that enzymatic partial disruption of islets with accutase followed by electroporation was effective for suppressing expression of a single gene .
TaqMan PCR primers and probes
5′- GGAAGCAACCCTCCTAAACC - 3′
5′ - TTTCTGCTTTTGCATTCGTG - 3′
5′ - [6-FAM] CATCTCCCAGGAGAGTCCAA [BHQ1a-6FAM] - 3′
5′ – AGAATGCCTCCTGGACCTTT - 3′
5′ – GGGGTGTCACGAGTGAACTT - 3′
5′ - [6-FAM] ACGCAGAAGAGGAAATTGGA [BHQ1a-6FAM] - 3′
5′ – ATTTGGCATGGAAACCAGAG - 3′
5′ – GTCACCCTTCTGGGAGTCAA - 3′
5′ - [6-FAM] AGAACCTGGAAAGGGCAGAT [BHQ1a-6FAM] - 3′
5′ – AGAGGAGGCGCCATGTCAG - 3′
5′ – CATTAGCGCATCACAGTCGC - 3′
5′ - 6-FAM] CAGAACCCATGCGGCAGCAA [BHQ1a-Q] - 3′
5′ – GTGGAAGGAAATTTGCGTGT - 3′
5′ – CCAGTGTGATGATGGTGAGG - 3′
5′ - [6-FAM] ACATAGTGTGGTGGTGCCCT [BHQ1a-Q] - 3′
5′ – AGGGTTTTCGTGGTTCACAT - 3′
5′ – CTGCCCATCATCATGACC - 3′
5′ - [6-FAM] CGATCCAGGTCCATGATGATG [BHQ1a-6FAM] - 3′
5′ – GAGTCAACGGATTTGGTCGT - 3′
5′ – TTGATTTTGGAGGGATCTCG - 3′
5′ - [6-FAM] CTGAGAACGGGAAGCTTGTC [BHQ1a-6FAM] - 3′
Major growth control pathways such as RB and p53 contain multiple upstream and downstream members as well as redundant family members that can compensate for loss of one another . Such complexity significantly complicates experiments designed to study pathway function and presents a challenge for developing practical applications that require modulation of one or more pathways. We targeted various combinations of the RB and p53 pathway members, including RB, p130, p107, p53, and p21 each with validated siRNAs (Dharmacon) at 25 nM or 50 nM concentrations, and also measured p14ARF transcript levels for changes in response to modulation of other genes. Indeed, we detected a modest induction of ARF gene expression after suppression of RB and p53 pathway members, an expected effect based on the known function of ARF to detect aberrant RB/p53 pathway signaling. Quantitative RT-PCR showed that at least 3 out of 5 targeted gene products were suppressed to levels considered standard in siRNA experiments. For example RB, p130 and p21 levels were suppressed by approximately 80% compared to control levels in samples treated for RB, p130, p107, p53 and p21 (Figure 2B). In multiple experiments (Figure 2B and data not shown) suppression of 4-5 genes resulted in variability in terms of reduction of each targeted mRNA. Likely contributing factors include saturation of the intracellular RNA interference machinery or induction of gene expression by activation of compensating pathway members in response to suppression of others (known to occur among the pocket proteins as well as among the p53 pathway members). We did not observe any significant increased toxicity when using higher total siRNA concentrations (up to 300 nM) required for these experiments. To confirm that electroporation of siRNA and gene suppression measured by mRNA was an indicator of decreased protein levels, Western blotting for RB protein was performed after treatment with control siRNAs and after combinations of targeting siRNAs. We found expected suppression of RB protein as suggested by the mRNA data, confirming the validity of the PCR data (Figure 2C).
One challenge facing the development of therapeutics to treat disorders of pancreatic islets is the difficulty of studying intact human islets. Although many important insights have and will continue to come from studies of rodent islets, the significant differences between islets from rodents and humans and the failure of many rodent findings to be conserved in human islet biology underscores the need for studies using human tissue. For example, adult rodent islets can readily undergo islet expansion in different circumstances including increased beta cell stress from Type 2 Diabetes . But adult human islets are more refractory, and efforts to demonstrate adult beta cell expansion have met with great difficulty . Moreover, rodents are genetically tractable and germline targeting of genes of interest is routine, but the limited lifespan of human islets in culture makes such studies using primary human tissue not possible at present. Therefore there is an unmet need for approaches to modify gene expression in intact human islets for translational application. The present study furthers that effort by demonstrating culture and transfection parameters that permit suppression of multiple genes at once, resulting in a phenotypic outcome not achievable with single gene manipulations.
This study builds on previously established approaches to transfect primary cells including islets using electroporation. In contrast to previous work , we used intact human islets transfected without accutase digestion and by modifying the electroporation parameters of voltage and frequency, pervasive suppression of targeted genes could be achieved without enzymatic disruption of the islet architecture. This advance is potentially beneficial because of the comparatively lesser manipulation of islets. Survival of electroporated islets and the maintenance of function after electroporation may have been aided in our study by the use of developed culture conditions and media designed to optimize islet survival and resistance to stress .
This study extends previous work  by showing that electroporation is a superior means of delivering siRNA into islets than liposome-based transfection. We compared the two approaches directly and electroporation caused a significantly greater reduction in targeted mRNA compared to lipofection. We show here that after optimization of siRNA concentrations and electroporation parameters two simultaneous knockdowns were possible to levels comparable to standards for easily transfected immortalized cell lines. Remarkably, we found that significant robust suppression of at least three genes simultaneously is possible using this method. Despite the preservation of islet structure and glucose responsiveness achieved with the present approach, it is likely that this system could be further optimized, for example by decreasing voltage in combination with use of newer siRNA modifications that endow greater transfection efficiency and potency [22, 23]. It is possible that subtle alterations in islet viability or function not detected in the assays used in this study would be better preserved at lower voltages.
Multiple gene suppression in the absence of damage to islet structure or glucose responsiveness allowed us to effectively target two central growth control pathways with inherent redundancies in each. Simultaneous compromise of the RB and p53 pathways led to entry of postmitotic islet cells into the cell cycle. This phenotypic outcome was a result of specific inhibition of the targeted genes and required suppression of multiple pathway members. These findings demonstrate the potential of transient suppression of multiple genes to have significant functional impact in situations where single gene targeting is inadequate. Future experiments will address global changes in islet differentiated and metabolic state after RB/p53 suppression by electroporation. Electroporation of human islets should prove a useful approach to aid the study of other important pathways containing multiple members.
The application of electroporation in optimized culture conditions is an effective approach to deliver siRNA molecules targeting multiple genes into a majority of cells within intact human islets. Benefits are that it is transient, avoids genetic integration and is well tolerated by islets. The capacity to significantly impact molecular pathways by targeting multiple genes within them should prove to be a valuable tool for both basic study and for practical applications.
Primary Islets cells and culture conditions
Primary human cadaveric islets were obtained from Prodo Labs. Typically islets were shipped overnight on ice 2-4 days after isolation. Upon receipt islets were diluted 50% in prewarmed 37°C PIM(S) media supplemented with PIM(ABS) and PIM(G) (complete) (all purchased from Prodo Laboratories) and centrifuged for 2 min 1200 rpm. Islets were washed and resupended at a concentration of 300-400 islet equivalents (IEQ) per ml in complete PIM(S) media in non-tissue culture treated flasks. Islets were incubated at 37°C in 5% CO2 with 50% media change every other day. For the samples used in our experiments the purity of the islets ranged between 85 and 90% in all samples. The average islet size was: 50-100 microns (74%); 100-200 microns (20%); 200-300 microns (5%); 300 microns and higher (1%).
All siRNAs were ON-TARGETplus SMARTpools purchased from Dharmacon, Thermo Scientific. The following siRNAs were used:
Lipid Transfection of islets
Islet transfection with cationic lipid was conducted by diluting 1 μl of Dharmafect 1 (T-2001 Life Techonogies) in 50 μl of PIM(S) followed by addition of siRNAs in 50 μl of PIM(S), vortexing and then allowing the mixture to sit at room temperature for 20 min. The lipid-siRNA mix was added to 400 IEQ in 400 μl complete media in 24-well low adhesion plates and incubated at 37°C in 5% CO2. The next day 1.5 ml of complete media was added to each well. The plates were then returned to the incubator to allow the islets to settle to the bottom and 1.25 ml of media was removed with a pipet. This process was repeated 3 times to remove the cationic lipid-siRNA following which the islets were returned to the incubator.
Electroporation of islets
Electroporation of islets was conducted using the Neon Transfection System (Life Technologies). Islets were centrifuged for 2 min 1200 rpm and then transferred to a 1.5 ml Eppendorf tube and washed with PBS and re-centrifuged. Islets were resuspended at a density of 400 IEQ per 10 μl in R buffer (Life Technologies) and typically electroporated once at approximately 1000-1100 Volts for 40 msec. For knockdown and EdU incorporation experiments the following concentrations of siRNA were used 25 nM RB, 25 nM p130, 25 nM p21, 50 nM ARF/CDKN2A, 50 nM p53, 50 nM p107 and siControl ranged from 25 nM-300 nM. Each batch of electroporated Islets was cultured individually in a single well of a 24-well low adhesion plates (per manufacturer recommendations) in 0.5 ml complete PIM(S) media. Viability was evaluated using ethidium bromide (Molecular Probes) diluted to 1:1000.
Evaluation of gene expression
All PCR data between samples were normalized to GAPDH expression levels and the level of gene knockdown was expressed relative to siCONTROL sample.
Islet samples for protein analysis were pelleted by centrifugation lysed in RIPA buffer and sonicated. After protein concentration was determined, 30 micrograms of protein were loaded per lane. For detection of Retinoblastoma protein blots were probed with 0.1 μg/mL of Human RB1 (MAB6495, R&D Systems) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (R &D Systems). GAPDH was similarly done with 0.05 μg/mL of Mouse Anti-Human GAPDH Monoclonal Antibody (MAB5718, R&D Systems).
EdU or Insulin staining
Islet assay for DNA synthesis was initiated by switching the culture media 48 hr after electroporation into PIM(R) media supplemented with PIM(ABS) and PIM(G) and 10% FBS (all purchased from Prodo Laboratories) containing 5 μM EdU (Life Technologies). Half the media was replaced each day containing 5 μM EdU. 1000 IEQ equivalents for each sample were harvested 7 days after electroporation by centrifuging for 2 min at 1200 rpm followed by aspiration of the media. The islet pellet was resuspended in the residual media and 25 μl of histogel (60°C) was added, mixed with the islets, and quickly placed on ice. The plug was fixed in 4% paraformaldhye-PBS overnight and then dehydrated in alcohol prior to paraffin embedding (Histotech Lab). Paraffin blocks were sectioned at 5 microns onto glass slides. Sections were deparaffinzed using orange oil and passaged through an alcohol series. EdU incorporation was assayed by staining for EdU using a Click-iT EdU Alexa Fluor 568 Imaging Kit (Invitrogen) according to manufacturer’s instructions. In the case of insulin staining deparaffinzed sections were blocked with 5% goat serum in 0.1% Triton PBS for 30 min and anti-pro-insulin C-peptide (Millipore, CBL94) 1:500 dilution and then incubated overnight. Sections were washed and stained with secondary antibody, goat-anti-mouse Alexa 556 (1:500) was used. For both EdU and antibody staining, cover-slips were mounted on sections with Vectashield Mounting Medium containing Dapi (Vector Lab). Digital photographs were taken using a 20X objective on an EVOS FL Cell Imaging System (Life Technologies).
Glucose Stimulation Insulin Secretion assay (GSIS)
Approximately 100 IEQ were placed into inserts. A glucose stimulation insulin secretion assay was conducted on islets 48 hr after electroporation. Approximately 100 IEQ were placed into millicell (Millipore Inc.) cell culture inserts in a 24 well plate. The minicell inserts were transferred into new wells containing 3 mM Glucose Media (50% Hams F10 (110 mg/dl glucose) 50% DMEM (no glucose), 7 mM Nabicarbonate, 0.75 mM CaCl2 2H2O and 10 μg/ml of Ciprofloxan. The inserts with islets were transferred to wells containing 3 mM Glucose Media for 1-2 min to wash out the original media. To remove insulin from the cultures, the islets were washed three separate times with 3 mM Glucose Media and then incubated overnight in the same media at 37 degrees with 5%CO2. The following morning islets were again washed by two 1 hr incubations in 3 mM Glucose Media before initiation of media collection to assay secretion of insulin into the media. For the first collection of the assay, the inserts plus islets were placed into 1 ml fresh 3 mM Glucose Media and incubated for one hour, and then the media was collected. Further samples were collected after 1 hr incubations in 20 mM Glucose Media. Finally the inserts plus islets were washed 2 times with 3 mM Glucose media and then incubated for a final 1 hr in 3 mM Glucose media and collected. The insert plus islets were then transfer to 10 mM Tris-1 mM EDTA pH 8.0 and islets collected from inserts and centrifuged at 180 g for 5 min. The islets were lysed by resuspension in 10 mM Tris-1 mM EDTA pH 8.0 plus 1% Triton-X containing protease inhibitors and vortexed. All samples collected were stored at -80°C until analysis.
ELISA to detect insulin was conducted using Millipore Human Insulin ELISA kit. The two PIM(S) samples from each matrix condition were pooled and assayed as a single sample. The protocol was followed as suggested by the manufacturer with the following modifications. Samples from 3 mM Glucose media were diluted 1:2, 12 mM Glucose media were diluted 1:5, 20 mM Glucose media diluted 1:10 and lysed islets diluted 1:20 prior to testing in ELISA assay. Plates were read at 450 nm absorbance on an Epoch Biotek plate reader.
DNA from lysed islets was quantitated using Invitrogen Quant-iT PicoGreen dsDNA assay kit. Samples were measured on a PerSeptive Biosytems Cyto-fluor and plotted against a standard curve of lambda DNA.
We gratefully acknowledge the constructive suggestions of Peter Lomedico, Richard Insel, Julia Greenstein and Laura Papuga of the Juvenile Diabetes Research Foundation. This work was funded in part by Juvenile Diabetes Research Institute grant 17-2012-515.
- Efrat S, Russ HA: Making beta cells from adult tissues. Trends Endocrinol Metab. 2012, 23 (6): 278-285. 10.1016/j.tem.2012.03.005.View ArticleGoogle Scholar
- Parnaud G, Hammar E, Ribaux P, Donath MY, Berney T, Halban PA: Signaling pathways implicated in the stimulation of beta-cell proliferation by extracellular matrix. Mol Endocrinol. 2009, 23 (8): 1264-1271. 10.1210/me.2009-0008.View ArticleGoogle Scholar
- Halban PA, German MS, Kahn SE, Weir GC: Current status of islet cell replacement and regeneration therapy. J Clin Endocrinol Metab. 2010, 95 (3): 1034-1043. 10.1210/jc.2009-1819.View ArticleGoogle Scholar
- Yang SN, Shi Y, Yang G, Li Y, Yu J, Berggren PO: Ionic mechanisms in pancreatic beta cell signaling. Cell Mol Life Sci. 2014, ᅟ: ᅟ-Google Scholar
- Hughes A, Jessup C, Drogemuller C, Mohanasundaram D, Milner C, Rojas D, Russ GR, Coates PT: Gene therapy to improve pancreatic islet transplantation for Type 1 diabetes mellitus. Curr Diabetes Rev. 2010, 6 (5): 274-284. 10.2174/157339910793360897.View ArticleGoogle Scholar
- Shapiro AM: Strategies toward single-donor islets of Langerhans transplantation. Curr Opin Organ Transplant. 2011, 16 (6): 627-631. 10.1097/MOT.0b013e32834cfb84.View ArticleGoogle Scholar
- Li F, Mahato RI: RNA interference for improving the outcome of islet transplantation. Adv Drug Deliv Rev. 2011, 63 (1–2): 47-68.View ArticleGoogle Scholar
- Jiao Y, Le Lay J, Yu M, Naji A, Kaestner KH: Elevated mouse hepatic betatrophin expression does not increase human beta-cell replication in the transplant setting. Diabetes. 2014, 63 (4): 1283-1288. 10.2337/db13-1435.View ArticleGoogle Scholar
- Bernal-Mizrachi E, Kulkarni RN, Scott DK, Mauvais-Jarvis F, Stewart AF, Garcia-Ocana A: Human beta-cell proliferation and intracellular signaling part 2: still driving in the dark without a road map. Diabetes. 2014, 63 (3): 819-831. 10.2337/db13-1146.View ArticleGoogle Scholar
- Fiaschi-Taesch NM, Salim F, Kleinberger J, Troxell R, Cozar-Castellano I, Selk K, Cherok E, Takane KK, Scott DK, Stewart AF: Induction of human beta-cell proliferation and engraftment using a single G1/S regulatory molecule, cdk6. Diabetes. 2010, 59 (8): 1926-1936. 10.2337/db09-1776.View ArticleGoogle Scholar
- Mulligan G, Jacks T: The retinoblastoma gene family: cousins with overlapping interests. Trends Genet. 1998, 14 (6): 223-229. 10.1016/S0168-9525(98)01470-X.View ArticleGoogle Scholar
- Lefebvre B, Vandewalle B, Longue J, Moerman E, Lukowiak B, Gmyr V, Maedler K, Kerr-conte J, Pattou F: Efficient gene delivery and silencing of mouse and human pancreatic islets. BMC Biotechnol. 2010, 10: 28-10.1186/1472-6750-10-28.View ArticleGoogle Scholar
- Barbu AR, Bodin B, Welsh M, Jansson L, Welsh N: A perfusion protocol for highly efficient transduction of intact pancreatic islets of Langerhans. Diabetologia. 2006, 49 (10): 2388-2391. 10.1007/s00125-006-0390-5.View ArticleGoogle Scholar
- Csete ME, Afra R, Mullen Y, Drazan KE, Benhamou PY, Shaked A: Adenoviral-mediated gene transfer to pancreatic islets does not alter islet function. Transplant Proc. 1994, 26 (2): 756-757.Google Scholar
- Giannoukakis N, Mi Z, Gambotto A, Eramo A, Ricordi C, Trucco M, Robbins P: Infection of intact human islets by a lentiviral vector. Gene Ther. 1999, 6 (9): 1545-1551. 10.1038/sj.gt.3300996.View ArticleGoogle Scholar
- Rehman KK, Wang Z, Bottino R, Balamurugan AN, Trucco M, Li J, Xiao X, Robbins PD: Efficient gene delivery to human and rodent islets with double-stranded (ds) AAV-based vectors. Gene Ther. 2005, 12 (17): 1313-1323. 10.1038/sj.gt.3302530.View ArticleGoogle Scholar
- Takahashi R, Ishihara H, Takahashi K, Tamura A, Yamaguchi S, Yamada T, Katagiri H, Oka Y: Efficient and controlled gene expression in mouse pancreatic islets by arterial delivery of tetracycline-inducible adenoviral vectors. J Mol Endocrinol. 2007, 38 (1–2): 127-136.View ArticleGoogle Scholar
- Harris SL, Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene. 2005, 24 (17): 2899-2908. 10.1038/sj.onc.1208615.View ArticleGoogle Scholar
- Dalboge LS, Almholt DL, Neerup TS, Vassiliadis E, Vrang N, Pedersen L, Fosgerau K, Jelsing J: Characterisation of age-dependent beta cell dynamics in the male db/db mice. PLoS One. 2013, 8 (12): e82813-10.1371/journal.pone.0082813.View ArticleGoogle Scholar
- Efrat S: Recent progress in generation of human surrogate beta cells. Curr Opin Endocrinol Diabetes Obes. 2013, 20 (4): 259-264.Google Scholar
- Scharp D, Arulmoli G, Taeidi P, Albert E, Avakian A, Sunshine H, Kucera C, McRaney D, Bondurant D, Haight B, Magaldi M: Survival and Function of Human Islets Cultured for 4 Weeks Post-Processing. International Pancreas and Islet Transplantation Association: 9/27/2013; Monterey California. 2013Google Scholar
- Corey DR: Chemical modification: the key to clinical application of RNA interference?. J Clin Invest. 2007, 117 (12): 3615-3622. 10.1172/JCI33483.View ArticleGoogle Scholar
- Kenski DM, Butora G, Willingham AT, Cooper AJ, Fu W, Qi N, Soriano F, Davies IW, Flanagan WM: siRNA-optimized modifications for enhanced In Vivo activity. Mol Ther Nucleic Acids. 2012, 1: e5-10.1038/mtna.2011.4.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.